Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.50 |
| ▸ | CCR5 | P51681 | 1/20 | 0.50 |
| ▸ | CCR8 | P51685 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.32 |
| ▸ | GRM5 | P41594 | 2/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2445894 | 0.80 | GRM5 (0.36) | CYP3A4GRM5CYP11B1 | |
| SCHEMBL8519877 | 0.74 | ALDH1A1 (0.37) | — | |
| Abametapir SCHEMBL351152 | 0.70 | CCR1 (1.00) | CCR1CCR5CCR8HDAC6METAP2 | |
| Abametapir SCHEMBL29374261 | 0.70 | CCR1 (1.00) | CCR1CCR5CCR8HDAC6METAP2 | |
| SCHEMBL23999759 | 0.68 | CCR1 (0.59) | CCR1CCR5CCR8HDAC6METAP2 | |
| SCHEMBL20031135 | 0.68 | CCR1 (0.54) | CCR1CCR5CCR8HDAC6METAP2 | |
| SCHEMBL12858928 | 0.68 | CYP11B1 (0.57) | CCR1CCR5CCR8HDAC6CYP3A4 | |
| SCHEMBL42126 | 0.67 | CCR1 (0.64) | CCR1CCR5CCR8HDAC6METAP2 | |
| SCHEMBL28852322 | 0.67 | CCR1 (0.52) | CCR1CCR5CCR8HDAC6METAP2 | |
| SCHEMBL16561248 | 0.67 | CCR1 (0.52) | CCR1CCR5CCR8HDAC6METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230461-A1 | 2,3-DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.5] NONANE DERIVATIVES | PFIZER INC. | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230461-A1 | 2,3-DIHYDRO-1H-INDEN-1-YL-2,7-DIAZASPIRO[3.5] NONANE DERIVATIVES | GIPR, GLP1R, GHSR | CCR1 1066/4885CCR5 814/4885CCR8 1738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.